Clinical Trials
Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States.
You can bring a community together to improve the impact of clinical trials – here’s how.
Underrepresented in cancer clinical trials, racial and ethnic minorities often miss out on the benefits of research participation. Educating potential participants on clinical trials can increase enrollment among populations that have been commonly overlooked.
Adolescent and young adult (AYA) patients aged 15 to 39 years are significantly underrepresented in cancer clinical trials.
Claire White, BSN, RN, CPHON, Laura Hynes, MA, BSN, RN, Lucy J. Gansauer, MSN, RN, OCN, CCRP, Mary Van Cleave, BSN, RN, OCN, Lavinia Dobrea, RN, MS, OCN, Amy Meleason, BSN, RN, OCN, Daniel McGough, BS, CCRP
What you need to know about discussing clinical trials with your patients.
Darolutamide, an investigational androgen receptor inhibitor, significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) compared with placebo in a large phase 3 clinical trial.
Dr James provides a review of recent report from the American Cancer Society Cancer Action Network on barriers to patient enrollment in therapeutic clinical trials for cancer and the consensus recommendations for overcoming these challenges.
Nurse and patient navigators are uniquely qualified to advocate for minority participation in oncology clinical trials.
© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512